Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: A randomized, double-blind, controlled trial by Tamtaji, O.R. et al.
lable at ScienceDirect
Clinical Nutrition xxx (xxxx) xxxContents lists avaiClinical Nutrition
journal homepage: ht tp: / /www.elsevier .com/locate/c lnuRandomized Control TrialsProbiotic and selenium co-supplementation, and the effects on
clinical, metabolic and genetic status in Alzheimer's disease: A
randomized, double-blind, controlled trial
Omid Reza Tamtaji a, Reza Heidari-soureshjani b, Naghmeh Mirhosseini c,
Ebrahim Kouchaki a, d, Fereshteh Bahmani e, Esmat Aghadavod e,
Maryam Tajabadi-Ebrahimi f, Zatollah Asemi e, *
a Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran
b Student Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran
c School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada
d Department of Neurology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
e Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran
f Faculty Member of Science Department, Science Faculty, Islamic Azad University, Tehran Central Branch, Tehran, Irana r t i c l e i n f o
Article history:
Received 12 September 2018
Accepted 30 November 2018
Keywords:
Alzheimer's disease
Cognitive function
Probiotic
Selenium
Metabolic proﬁles* Corresponding author. Fax: þ98 31 55540022.
E-mail address: asemi_r@yahoo.com (Z. Asemi).
https://doi.org/10.1016/j.clnu.2018.11.034
0261-5614/© 2018 Elsevier Ltd and European Society
Please cite this article as: Tamtaji OR et al., Pr
in Alzheimer's disease: A randomized, doubs u m m a r y
Background and aims: Combined probiotic and selenium supplementation may improve Alzheimer's
disease (AD) by correcting metabolic abnormalities, and attenuating inﬂammation and oxidative stress.
This study aimed to determine the effects of probiotic and selenium co-supplementation on cognitive
function and metabolic status among patients with AD.
Methods: This randomized, double-blind, controlled clinical trial was conducted among 79 patients with
AD. Patients were randomly assigned to receive either selenium (200 mg/day) plus probiotic containing
Lactobacillus acidophilus, Biﬁdobacterium biﬁdum, and Biﬁdobacterium longum (2  109 CFU/day each)
(n ¼ 27), selenium (200 mg/day) (n ¼ 26) or placebo (n ¼ 26) for 12 weeks.
Results: Selenium supplementation, compared with the placebo, signiﬁcantly reduced serum high
sensitivity C-reactive protein (hs-CRP) (P < 0.001), insulin (P ¼ 0.001), homeostasis model of assessment-
insulin resistance (HOMA-IR) (P ¼ 0.002), LDL-cholesterol (P ¼ 0.04) and total-/HDL-cholesterol ratio
(P ¼ 0.004), and signiﬁcantly increased total glutathione (GSH) (P ¼ 0.001) and the quantitative insulin
sensitivity check index (QUICKI) (P ¼ 0.01). Compared with only selenium and placebo, probiotic and
selenium co-supplementation resulted in a signiﬁcant increase in mini-mental state examination score
(þ1.5 ± 1.3 vs. þ0.5 ± 1.2 and 0.2 ± 1.1, respectively, P < 0.001). Probiotic plus selenium intake resulted
in a signiﬁcant reduction in hs-CRP (1.6 ± 1.4 vs. 0.8 ± 1.0 and þ0.1 ± 0.5 mg/L, respectively,
P < 0.001), and a signiﬁcant increase in total antioxidant capacity (þ89.4 ± 129.6 vs. þ20.0 ± 62.5
and 0.7 ± 27.2 mmol/L, respectively, P ¼ 0.001) and GSH (þ122.8 ± 136.5 vs. þ102.2 ± 135.2
and þ1.5 ± 53.2 mmol/L, respectively, P ¼ 0.001) compared with only selenium and placebo. In addition,
subjects who received probiotic plus selenium supplements had signiﬁcantly lower insulin levels
(2.1 ± 2.5 vs. 1.0 ± 1.3 and þ0.7 ± 2.0 mIU/mL, respectively, P < 0.001), HOMA-IR (0.5 ± 0.6
vs. 0.2 ± 0.3 and þ0.1 ± 0.4, respectively, P < 0.001), and higher QUICKI (þ0.01 ± 0.01
vs. þ0.005 ± 0.007 and 0.002 ± 0.01, respectively, P < 0.006) compared with only selenium and pla-
cebo. Additionally, probiotic and selenium co-supplementation resulted in a signiﬁcant reduction in
serum triglycerides (17.9 ± 26.1 vs. 3.5 ± 33.9 and þ0.3 ± 9.3 mg/dL, respectively, P ¼ 0.02), VLDL-
(3.6 ± 5.2 vs. 0.7 ± 6.8 and þ0.05 ± 1.8 mg/dL, respectively, P ¼ 0.02), LDL- (8.8 ± 17.8 vs. 8.1 ± 19.2
and þ2.7 ± 19.0 mg/dL, respectively, P ¼ 0.04) and total-/HDL-cholesterol (0.3 ± 0.7 vs. 0.4 ± 0.9
and þ0.3 ± 0.6, respectively, P ¼ 0.005) compared with only selenium and placebo.
Conclusions: Overall, we found that probiotic and selenium co-supplementation for 12 weeks to patients
with AD improved cognitive function and some metabolic proﬁles.for Clinical Nutrition and Metabolism. All rights reserved.
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Alzheimer's disease (AD) is a progressive and fatal brain disease
coupled with the reduction of cognitive ability and loss of memory
[1]. It is characterized by the presence of amyloid-b and hyper-
phosphorylated tau-containing neuroﬁbrillary tangles in patho-
logical brain tissue [2]. Elevated production of reactive oxygen
species (ROS) and inﬂammatory markers, decreased antioxidant
systems, and reduced efﬁciency in repairing mechanisms have
been associated with AD [3,4]. In addition, prior studies have re-
ported that metabolic abnormalities such as hyperinsulinemia,
hyperglycemia, decreased insulin sensitivity [5] and dyslipidemia
[6] are linked to the pathogenesis and progress of AD.
Earlier, it was reported that the increased permeability of the
gut and bloodebrain barrier induced by microbiota dysbiosis may
affect AD pathogenesis and other neurodegenerative disorders
associated with aging [7]. In addition, selenium, which is an
important trace element and plays a critical role in various redox
and metabolic processes, has been shown to be used in the pre-
vention of the onset and progression of AD [8]. The beneﬁcial ef-
fects of single selenium administration on cognitive function in an
animal model of AD [9] and probiotic containing Lactobacillus aci-
dophilus, Lactobacillus casei, Biﬁdobacterium biﬁdum, and Lactoba-
cillus fermentum (2  109 CFU/g each for 12 weeks) on cognitive
function and metabolic proﬁles in people with AD [10] were re-
ported. Previous studies have demonstrated that joint probiotic and
selenium supplementation is much more efﬁcient in inﬂuencing
metabolic proﬁles than single selenium or probiotic supplemen-
tation. The administration of selenium-enriched probiotics has
shown a better effect on lipid proﬁles, antioxidant status, histo-
pathological lesions, and the gene expression related to metabolic
proﬁles in mice fed a high-fat diet, when compared to the ingestion
of each supplement alone [11]. In another study, selenium-enriched
probiotics supplementation in piglets, under high-temperature
environments, signiﬁcantly improved antioxidant status, immune
function, and selenoprotein gene expression rather than adminis-
tering sodium selenite or probiotics alone [12].
Considering the antioxidant and anti-inﬂammatory effects of
probiotic and selenium, we hypothesized that probiotic and sele-
nium might be useful on brain function and metabolic proﬁles in
AD. However, data on studies investigating the impact of probiotic
and selenium co-supplementation on biomarkers of inﬂammation
and oxidative stress, glycemic control, lipid proﬁles, and gene
expression related to metabolic status in AD are scarce. Therefore,
this study also evaluates the effects of probiotic and selenium co-
supplementation on metabolic proﬁles and gene expression
related to metabolic status in AD.2. Subjects and methods
2.1. Trial design and ethics statements
This was a 12-week randomized, double-blind, controlled clin-
ical trial that was registered in the Iranian website for registration
of clinical trials (http://www.irct.ir: IRCT20170612034497N5) and
was conducted accordance with the Declaration of Helsinki be-
tween December 2017 and July 2018. Informed consent wasrobiotic and selenium co-supp
le-blind, controlled trial, Clinreceived from all patients. The research was approved by the ethics
committee of Kashan University of Medical Sciences (KAUMS).
2.2. Participants
Participants were eligible for inclusion if they were 55e100
years of age diagnosis of AD at the Golabchi Welfare Organization
(Kashan, Iran), and Madar, Shayestegan and Amin Welfare Orga-
nizations (Shahrekord, Iran). AD patients were diagnosed following
the NINDS-ADRDA criteria [13] and revised criteria from the Na-
tional Institute on Aging-Alzheimer's Association [14]. Patients
with metabolic syndrome, diabetes, cardiovascular disease, chronic
infections, consuming probiotic and/or synbiotic supplements
within 8 weeks prior to the study, taking other forms of probiotics
including probiotic yogurt, keﬁr and other fermented foods, and
taking antioxidants supplements such as selenium and vitamin E
were excluded.
2.3. Study design
Firstly, all patients were matched for BMI and age. Then, they
were randomly assigned to receive either selenium (200 mg/day)
plus probiotic containing L. acidophilus, B. biﬁdum, and Biﬁdo-
bacterium longum (2  109 CFU/day each) (n ¼ 27), selenium
(200 mg/day) (n ¼ 26) or placebo (n ¼ 26) for 12 weeks. Probiotic
and selenium and the placebo (starch) were produced by Tak Gen
Zist Company (Tehran, Iran), Webber Naturals Pharmaceutical
Company (Coquitlam, Canada) and Tak Gen Zist Company (Teh-
ran, Iran), respectively. They were completely identical in terms
of their appearance, color, shape, size, smell and taste and
packaging. Random assignment was conducted using computer-
generated numbers. The randomized allocation sequence,
enrolling participants and allocating them into intervention
groups were conducted by a trained staff at the clinic. Since the
study subjects were institutionalized because of the nature of
their disease, compliance was assessed through the checklist
ﬁlled by a trained staff who was responsible to give the patients
their supplements every day. Dietary intakes (3-day food re-
cords) of all participants were completed at baseline, weeks 4, 8
and 12 of the intervention by a trained researcher. Daily macro-
and micro-nutrient intakes were analyzed by nutritionist IV
software (First Databank, San Bruno, CA).
2.4. Assessment of anthropometric measures
Weight and height of participants were determined using a
standard scale (Seca, Hamburg, Germany) at the beginning of the
study and after 12 weeks’ treatment. BMI was calculated as weight
in kg divided by height in meters squared.
2.5. Assessment of outcomes
The primary outcome measurement was Mini-Mental State
Examination (MMSE) and the secondary outcome measurements
were biomarkers of inﬂammation and oxidative stress, and meta-
bolic proﬁles. The MMSE was used to assess cognition in AD
subjects.lementation, and the effects on clinical, metabolic and genetic status
ical Nutrition, https://doi.org/10.1016/j.clnu.2018.11.034
O.R. Tamtaji et al. / Clinical Nutrition xxx (xxxx) xxx 32.6. Assessment of biochemical parameters
Twelve-hour fasting blood samples were taken by venipuncture
at weeks 0 and 12 of the intervention at Kashan reference labora-
tory. Serum high sensitivity C-reactive protein (hs-CRP) levels were
quantiﬁed using a commercial ELISA kit (LDN, Nordhorn, Germany)
with the intra- and inter-assay coefﬁcient variances (CVs) lower
than 6.5%. Plasma nitric oxide (NO) were quantiﬁed by the Griess
method [15]. Plasma total antioxidant capacity (TAC) using the
method of ferric reducing antioxidant power method developed by
Benzie and Strain [16], total glutathione (GSH) by the method of
Beutler et al. [17] and malondialdehyde (MDA) levels using the
thiobarbituric acid reactive substance method [18] with inter- and
intra-assay CVs lower than 5%were evaluated. To determine fasting
plasma glucose (FPG) and lipid proﬁles, we used available kits (Pars
Azmun, Tehran, Iran) with inter- and intra-assay CVs lower than 5%.
Circulating levels of insulin were determined using an ELISA kit
(Monobind, California, USA) with the intra- and inter-assay CVs 3.3
and 4.8%, respectively. The homeostatic model of assessment for
insulin resistance (HOMA-IR) and the quantitative insulin sensi-
tivity check index (QUICKI) were calculated according to suggested
formulas.
2.7. Isolation of lymphocyte cells
Lymphocyte cells were isolated from blood using 50% Percoll
(SigmaeAldrich, Dorset, UK). Cell count and viability test were
conducted using trypan blue [19].
2.8. RNA extraction and real-time PCR (RT-PCR)
RNX-plus kit (Cinnacolon, Tehran, Iran) was used to extract RNA
from blood samples. RNA suspension was frozen of 20 C until
cDNAwas derived. Following the extraction of total RNAs from each
sample, RNA quantiﬁcation was performed using UV spectropho-
tometer. Each sample OD 260/280 ratio was considered to be be-
tween 1.7 and 2.1, demonstrating no contamination with either
protein or DNA [19]. The isolated RNA was reverse transcribed to
cDNA library, using moloney murine leukemia virus reverse tran-
scriptase (RT). Gene expressions of tumor necrosis factor alpha
(TNF-a), interleukin-8 (IL-8), transforming growth factor beta (TGF-
b), peroxisome proliferator-activated receptor gamma (PPAR-g) and
low-density lipoprotein receptor (LDLR) were assessed by quanti-
tative RT-PCR in peripheral bloodmononuclear cells (PBMCs), using
the LightCycler technology (Roche Diagnostics, Rotkreuz,
Switzerland) with SYBR green detection and Amplicon Kit (Table 1).Table 1
Speciﬁc primers used for real-time quantitative PCR.
Gene Primer Product
size (bp)
Annealing
temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
TNF-a F: GTCAACCTCCTCTCTGCCAT 188 52
R: CCAAAGTAGACCTGCCCAGA
IL-8 F: GCAGAGGGTTGTGGAGAAGT 150 56
R: ACCCTACAACAGACCCACAC
TGF-b F: TTGAGACTTTTCCGTTGCCG 227 56
R: CGAGGTCTGGGGAAAAGTCT
PPAR-g F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
LDLR F: ACTTACGGACAGACAGACAG 223 57
R: GGCCACACATCCCATGATTC
GAPDH, glyceraldehyde-3-Phosphate dehydrogenase; IL-8, interleukin-8; LDLR,
low-density lipoprotein receptor; PPAR-g, peroxisome proliferator-activated re-
ceptor gamma; TNF-a, tumor necrosis factor alpha; TGF-b, transforming growth
factor beta.
Please cite this article as: Tamtaji OR et al., Probiotic and selenium co-supp
in Alzheimer's disease: A randomized, double-blind, controlled trial, ClinGlyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers
were used as a housekeeping gene. Primer Express Software
(Applied Biosystems, Foster City, USA) and Beacon designer soft-
ware (Takaposizt, Tehran, Iran) were used to design primers.
Relative transcription levels were calculated using the method of
Pffaﬁ.
2.9. Sample size
To calculate the sample size, we used the standard formula
suggested for parallel clinical trials by considering type one error
(a) of 0.05 and type two error (b) of 0.20 (power ¼ 80%). Based on a
previous study [10], we used a standard deviation (SD) of 2.80 and a
difference in mean (d) of 2.25, considering MMSE as the key vari-
able. Based on this, we needed 25 patients in each group. Assuming
20% dropouts in each group, the ﬁnal sample size was determined
to be 30 patients per group.
2.10. Statistical methods
Anthropometric measures, macro- and micro-nutrient dietary
intakes, cognitive function, metabolic proﬁles and gene expression
related to inﬂammation, insulin and lipid were compared among
the three groups, using ANOVA test with Bonferoni post hoc pair-
wise comparisons. The normality of model residual was tested
using the KolmogoroveSmirnov test. The P-value of<0.05 were
considered statistically signiﬁcant. All statistical analyses used the
Statistical Package for Social Science version 18 (SPSS Inc., Chicago,
Illinois, USA).
3. Results
Four participants in selenium group, 3 participants in probiotic
plus selenium group, and 4 participants in placebo group withdraw
from the trial, due to personal reasons, and ﬁnally 79 participants
[probiotic plus selenium (n ¼ 27), selenium (n ¼ 26) and placebo
(n ¼ 26)] completed the study (Fig. 1). On average, the rate of
compliance in our study was high, such that 100% of supplements
and placebos were taken throughout the study in three groups.
Mean age, height, weight and BMI at baseline and end-of-trial
were not statistically different among the three groups (Table 2).
Based on the 3-day dietary records obtained at study baseline,
end-of-trial and throughout the trial, we found no signiﬁcant dif-
ferences in mean dietarymacro- andmicro-nutrient intakes among
the three groups (Data not shown).
3.1. Cognitive assessment
Compared with only selenium and placebo, probiotic and sele-
nium co-supplementation resulted in a signiﬁcant improvement in
MMSE score (þ1.5 ± 1.3 vs. þ0.5 ± 1.2 and 0.2 ± 1.1, respectively,
P < 0.001) (Table 3).
3.2. Biochemical measurements
Selenium supplementation, compared with the placebo, signif-
icantly reduced serum hs-CRP (P < 0.001), insulin (P ¼ 0.001),
HOMA-IR (P ¼ 0.002), LDL-cholesterol (P ¼ 0.04) and total-/HDL-
cholesterol ratio (P ¼ 0.004), and signiﬁcantly increased GSH
(P¼ 0.001) and QUICKI (P¼ 0.01) (Table 3). Probiotic plus selenium
intake resulted in a signiﬁcant reduction in serum hs-CRP
(1.6 ± 1.4 vs. 0.8 ± 1.0 and þ0.1 ± 0.5 mg/L, respectively,
P < 0.001), and a signiﬁcant increase in TAC (þ89.4 ± 129.6
vs. þ20.0 ± 62.5 and 0.7 ± 27.2 mmol/L, respectively, P ¼ 0.001)
and GSH levels (þ122.8 ± 136.5 vs. þ102.2 ± 135.2lementation, and the effects on clinical, metabolic and genetic status
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Fig. 1. Summary of patient ﬂow.
Table 2
General characteristics of study participants.a
Placebo group (n ¼ 26) Selenium group (n ¼ 26) Probiotic plus selenium group (n ¼ 27) Pb
Age (y) 78.5 ± 8.0 78.8 ± 10.2 76.2 ± 8.1 0.51
Height (cm) 158.9 ± 10.3 159.5 ± 5.6 159.5 ± 5.9 0.94
Weight at study baseline (kg) 54.3 ± 7.5 54.0 ± 5.4 52.9 ± 9.8 0.79
Weight at end-of-trial (kg) 54.1 ± 7.6 55.7 ± 5.5 52.8 ± 9.7 0.81
Weight change (kg) 0.2 ± 1.2 0.3 ± 0.5 0.1 ± 0.5 0.68
BMI at study baseline (kg/m2) 21.5 ± 2.4 21.2 ± 1.2 20.7 ± 3.2 0.49
BMI at end-of-trial (kg/m2) 21.5 ± 2.5 21.1 ± 1.3 20.7 ± 3.2 0.51
BMI change (kg/m2) 0.1 ± 0.5 0.1 ± 0.2 0.1 ± 0.2 0.67
a Data are means ± SDs.
b Obtained from ANOVA test.
O.R. Tamtaji et al. / Clinical Nutrition xxx (xxxx) xxx4and þ1.5 ± 53.2 mmol/L, respectively, P ¼ 0.001) compared with
only selenium and placebo. In addition, subjects who received
probiotic plus selenium supplements had signiﬁcantly lower serum
insulin levels (2.1 ± 2.5 vs. 1.0 ± 1.3 and þ0.7 ± 2.0 mIU/mL,
respectively, P < 0.001), HOMA-IR (0.5 ± 0.6 vs. 0.2 ± 0.3
and þ0.1 ± 0.4, respectively, P < 0.001), and higher QUICKI
(þ0.01 ± 0.01 vs. þ0.005 ± 0.007 and 0.002 ± 0.01, respectively,
P < 0.006) compared with only selenium and placebo. Additionally,
probiotic and selenium co-supplementation resulted in a signiﬁ-
cant reduction in serum triglycerides (17.9 ± 26.1 vs. 3.5 ± 33.9
and þ0.3 ± 9.3 mg/dL, respectively, P ¼ 0.02), VLDL- (3.6 ± 5.2
vs. 0.7 ± 6.8 and þ0.05 ± 1.8 mg/dL, respectively, P ¼ 0.02), LDL-
(8.8 ± 17.8 vs. 8.1 ± 19.2 and þ2.7 ± 19.0 mg/dL, respectively,
P ¼ 0.04) and total-/HDL-cholesterol (0.3 ± 0.7 vs. 0.4 ± 0.9
and þ0.3 ± 0.6, respectively, P ¼ 0.005) compared with only sele-
nium and placebo. Probiotic and selenium co-supplementation
signiﬁcantly increased MMSE score (P ¼ 0.007) and QUICKIPlease cite this article as: Tamtaji OR et al., Probiotic and selenium co-supp
in Alzheimer's disease: A randomized, double-blind, controlled trial, Clin(P ¼ 0.03), and signiﬁcantly reduced hs-CRP (P ¼ 0.01), FPG
(P ¼ 0.04), insulin (P ¼ 0.04) and HOMA-IR (P ¼ 0.02) compared
with only selenium.
3.3. Gene expression related to inﬂammation, insulin and lipid
metabolism
Probiotic and selenium co-supplementation signiﬁcantly
downregulated gene expression of TNF-a (P ¼ 0.005) in PBMCs of
patients with AD; however, it did not affect gene expression of IL-8
and TGF-b (Fig. 2).
RT-PCR quantitative results showed a signiﬁcant upregulation of
gene expression of PPAR-g (P ¼ 0.002) and LDLR (P ¼ 0.003) in
PBMCs of patients with AD following probiotic and selenium co-
supplementation compared with only selenium and placebo
(Fig. 3). In addition, selenium supplementation signiﬁcantly
increased gene expression of LDLR compared with the placebo.lementation, and the effects on clinical, metabolic and genetic status
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Table 3
Cognitive function, biomarkers of inﬂammation and oxidative stress, andmetabolic proﬁles at baseline and after the 12-week intervention in patients with Alzheimer's disease
that received either probiotic plus selenium, selenium supplements or placebo.
Placebo group (n ¼ 26) Selenium group (n ¼ 26) Probiotic plus selenium group (n ¼ 27) Pc
Wk0 Wk12 Change Wk0 Wk12 Change Wk0 Wk12 Change
MMSE 9.3 ± 4.1 9.1 ± 4.4 0.2 ± 1.1 9.9 ± 4.0 10.4 ± 4.2 0.5 ± 1.2 9.4 ± 3.5 10.9 ± 3.8 1.5 ± 1.3b,a <0.001
hs-CRP (mg/L) 4.8 ± 1.3 4.9 ± 1.3 0.1 ± 0.5 4.9 ± 1.9 4.1 ± 1.6 0.8 ± 1.0a 5.5 ± 1.5 3.9 ± 0.9 1.6 ± 1.4b,a <0.001
NO (mmol/L) 35.3 ± 3.7 35.3 ± 3.8 0.03 ± 1.8 33.2 ± 3.8 33.8 ± 5.0 0.6 ± 5.6 33.5 ± 5.2 34.1 ± 4.8 0.6 ± 4.3 0.81
TAC (mmol/L) 834.3 ± 92.0 833.6 ± 92.8 0.7 ± 27.2 821.2 ± 63.9 841.2 ± 62.2 20.0 ± 62.5 815.0 ± 77.4 904.4 ± 109.2 89.4 ± 129.6b,a 0.001
GSH (mmol/L) 403.3 ± 89.5 404.8 ± 105.0 1.5 ± 53.2 444.1 ± 80.3 546.3 ± 99.3 102.2 ± 135.2a 458.9 ± 96.9 581.8 ± 96.7 122.8 ± 136.5b,a 0.001
MDA (mmol/L) 2.7 ± 0.4 2.7 ± 0.4 0.002 ± 0.2 2.8 ± 0.2 2.8 ± 0.3 0.009 ± 0.3 2.7 ± 0.3 2.6 ± 0.2 0.1 ± 0.4 0.10
FPG (mg/dL) 88.7 ± 9.8 89.7 ± 9.5 1.1 ± 10.8 86.3 ± 13.7 87.9 ± 6.6 1.5 ± 10.0 91.7 ± 4.3 87.6 ± 8.6 4.1 ± 9.5 0.08
Insulin (mIU/mL) 11.4 ± 2.1 12.1 ± 2.1 0.7 ± 2.0 11.3 ± 2.2 10.3 ± 1.9 1.0 ± 1.3a 11.7 ± 1.3 9.7 ± 2.5 2.1 ± 2.5a <0.001
HOMA-IR 2.5 ± 0.6 2.6 ± 0.5 0.1 ± 0.4 2.4 ± 0.5 2.2 ± 0.6 0.2 ± 0.3a 2.7 ± 0.4 2.2 ± 0.6 0.5 ± 0.6a <0.001
QUICKI 0.33 ± 0.01 0.33 ± 0.01 0.002 ± 0.01 0.33 ± 0.01 0.34 ± 0.01 0.005 ± 0.007 0.33 ± 0.007 0.34 ± 0.01 0.01 ± 0.01 <0.001
Triglycerides (mg/dL) 116.9 ± 38.3 117.2 ± 36.2 0.3 ± 9.3 112.4 ± 35.5 108.9 ± 26.3 3.5 ± 33.9 126.9 ± 30.1 108.9 ± 23.3 17.9 ± 26.1a 0.02
VLDL-cholesterol (mg/dL) 23.4 ± 7.7 23.4 ± 7.2 0.05 ± 1.8 22.5 ± 7.1 21.8 ± 5.3 0.7 ± 6.8 25.4 ± 6.0 21.8 ± 4.7 2.6 ± 5.2a 0.02
Total cholesterol (mg/dL) 185.4 ± 33.8 186.2 ± 34.1 0.8 ± 20.6 184.9 ± 37.9 177.0 ± 34.7 7.9 ± 24.5 203.9 ± 34.2 192.0 ± 30.6 11.9 ± 18.9 0.09
LDL-cholesterol (mg/dL) 114.1 ± 34.5 116.8 ± 34.4 2.7 ± 19.0 117.9 ± 34.9 109.7 ± 32.9 8.1 ± 19.2a 129.8 ± 31.1 121.0 ± 27.9 8.8 ± 17.9a 0.04
HDL-cholesterol (mg/dL) 47.9 ± 7.8 45.9 ± 8.9 2.0 ± 4.3 44.5 ± 10.5 45.5 ± 8.7 1.0 ± 6.9 48.7 ± 4.5 49.2 ± 5.4 0.5 ± 5.9 0.15
Total-/HDL-cholesterol 3.9 ± 0.9 4.2 ± 1.2 0.3 ± 0.6 4.3 ± 1.2 3.9 ± 0.8 0.4 ± 0.9a 4.2 ± 0.9 3.9 ± 0.8 0.3 ± 0.7a 0.005
Data are mean ± SDs.
FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model of assessment-insulin resistance; HDL-cholesterol, high density lipoprotein-cholesterol; Hs-
CRP, high sensitivity C-reactive protein; LDL-cholesterol, low density lipoprotein-cholesterol; MMSE, mini-mental state examination; MDA, malondialdehyde; NO, nitric
oxide; QUICKI, quantitative insulin sensitivity check index; VLDL-cholesterol, very low density lipoprotein-cholesterol; SGA, subjective global assessment; TAC, total anti-
oxidant capacity.
a Signiﬁcant different from the placebo group.
b Signiﬁcant different from the selenium group.
c Obtained from ANOVA test.
Fig. 2. Effect of the 12-week supplementation with probiotic plus selenium, selenium or placebo on expression ratio of TNF-a, IL-8 and TGF-b gene in PBMCs of patients with AD.
Fig. 3. Effect of the 12-week supplementation with probiotic plus selenium, selenium or placebo on expression ratio of PPAR-g and LDLR gene in PBMCs of patients with AD. AD,
Alzheimer's disease; IL-8, interleukin-8; LDLR, low-density lipoprotein receptor; PBMCs, peripheral blood mononuclear cells; PPAR-g, peroxisome proliferator-activated receptor
gamma; TNF-a, tumor necrosis factor alpha; TGF-b, transforming growth factor beta.
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The current study demonstrated that probiotic and selenium co-
supplementation for 12 weeks to patients with AD had favorable
effects on MMSE score, hs-CRP, TAC, GSH, markers of insulin
metabolism, triglycerides, VLDL-, LDL-, total-/HDL-cholesterol, but
it did not affect other biomarkers of inﬂammation and oxidative
stress, FPG and other lipid proﬁles. In addition, co-supplementation
signiﬁcantly reduced gene expression of TNF-a, and signiﬁcantly
increased gene expression of PPAR-g and LDLR, but did not affect
gene expression of IL-8 and TGF-b.To the best of our knowledge,
this study is the ﬁrst evaluating the beneﬁcial effects of probiotic
and selenium co-supplementation on cognitive function, bio-
markers of inﬂammation and oxidative stress, metabolic status and
gene exopression related to inﬂammation, insulin and lipid in pa-
tients with AD.
4.1. Effects on cognitive function
Patients with AD are susceptible to multiple complications such
as increased inﬂammatorymarkers and oxidative damage,mortality
[20], microvascular disease, dyslipidemia and insulin resistance [21].
Our results indicated that probiotic and selenium co-
supplementation for 12 weeks to patients with AD improved
MMSE score. Data on the effects of probiotic and selenium supple-
mentation on brain behavioral phenomena are limited. We have
previously shown that taking probiotic for 12 weeks by patients
with AD was associated with improved cognitive function [10]. In
another study, multispecies probiotic intake for 4 weeks among
patients with AD signiﬁcantly improved gut bacteria composition
and circulating levels of tryptophan [22]. In addition, selenium-
methylselenocysteine signiﬁcantly ameliorated cognitive deﬁcits
by attenuating oxidative stress and metal dyshomeostasis in a mu-
rine model of AD [23]. Long-term supplementation with selenium-
enriched yeast signiﬁcantly improved cognitive impairment, and
mitigates tau pathology in a triple transgenic mouse model of AD
[9]. Probiotics may change gut microbiota and subsequently can
improve cognitive function through contributing in the expression
of receptors producing neurotransmitters and neuromodulators.
Through inducing gutebrain axis, probiotics also may affect
neurotransmitter synthesis including gamma-aminobutyric acid,
norepinephrine, serotonin, dopamine and acetylcholine [24]. Sele-
nium intake may improve normal cellular function by reduced pro-
oxidants and increased antioxidants levels in the brain [25].
4.2. Effects on biomarkers of inﬂammation and oxidative stress
Findings of the current study shown that probiotic and selenium
co-supplementation for 12 weeks to patients with AD was associ-
ated with a signiﬁcant decrease in hs-CRP and a signiﬁcant increase
in TAC and GSH, but did not affect NO and MDA levels. In addition,
co-supplementation reduced gene expression of TNF-a, but did not
affect gene expression of IL-8 and TGF-b. In a study conducted by
Liu et al. [26], selenium-glutathione-enriched probiotics was
effective in attenuating liver ﬁbrosis by activating silent informa-
tion regulator 1 signaling and attenuating hepatic oxidative stress,
inﬂammation and mitogen-activated protein kinases)MAPK(
signaling. In addition, selenium-enriched probiotics could protect
the liver from ﬁbrosis by attenuating hepatic oxidative stress, and
inhibiting hepatic inﬂammation as well as inducing apoptosis of
hepatic stellate cells [27]. Earlier, the beneﬁcial effects of probiotic
and selenium supplementation on some biomarkers of inﬂamma-
tion and oxidative stress in patients with AD was reported [10].
Probiotic intake may reduce inﬂammation and oxidative damage
through their metal ion chelating ability, antioxidant systems suchPlease cite this article as: Tamtaji OR et al., Probiotic and selenium co-supp
in Alzheimer's disease: A randomized, double-blind, controlled trial, Clinas enhancing activity of superoxide dismutase and catalase, regu-
lating signaling pathways including MAPKs and nuclear factor-
kappaB, and decreased levels ROS-scavenging proteins [28].
Furthermore, selenium may attenuate inﬂammation and oxidative
stress by the enhancing of glutathione peroxidase activity, reducing
nuclear factor-kappaB activation, altering the metabolism of
arachidonic acid and inhibiting MAP kinase pathways [29].
4.3. Effects on glycemic control and lipid proﬁles
The current study documented that taking probiotic plus sele-
nium supplements for 12 weeks by patients with AD resulted in a
signiﬁcant improvement in markers of insulin metabolism, tri-
glycerides, VLDL-, LDL- and total-/HDL-cholesterol, but it did not
inﬂuence FPG, total- and HDL-cholesterol levels. In addition, co-
supplementation increased gene expression of PPAR-g and LDLR.
In a meta-analysis conducted by Kasinska et al. [30], a signiﬁcant
effect of probiotics on decreasing HbA1c levels and HOMA-IR in
patients with type 2 diabetes mellitus was seen, but did not have a
signiﬁcant effect on FPG, insulin, and lipid proﬁles. In addition, we
have previously reported that selenium supplementation to patients
with metabolic diseases did not inﬂuence lipid proﬁles [31]. The
inconclusive results of different studies might be correlated to their
methodology like doses, administering combined versus individual
nutrients, duration of intervention and other possible confounding
factors. Insulin-mimetic and antilipidemic effects of probiotic sup-
plement may be mediated by reducing oxidative stress and pro-
inﬂammatory markers [32], increasing b-oxidation of long-chain
fatty acids in liver and muscle tissues [33]. Selenium intake may
improve markers of insulin and lipid metabolism through inhibiting
the expression of cyclooxygenase-2 and P-selectin, and increased
gene expression of few enzymes including very long chain dehy-
drogenase and medium chain Acyl-CoA dehydrogenase [34].
The current study had some limitations. We did not assess the
compliance to probiotic and selenium intake through quantifying
fecal bacteria loads and plasma selenium levels. Due to limited
funding, we did not examine the effects of probiotic and selenium
co-supplementation on gene expression related to oxidative stress.
In the current study, we have evaluated the effects of selenium
alone, and selenium plus probiotic on clinical, metabolic and ge-
netic status in patients with AD. A fourth group who was receiving
probiotic alone would be ideal to give a full 2  2 factorial design,
however due to the limitations of this study, we focused on eval-
uating the synergistic effects of selenium and probiotic on clinical,
metabolic and genetic status in patients with AD.
4.4. Conclusions
Overall, the current study demonstrated that probiotic and se-
lenium co-supplementation for 12 weeks to patients with AD had
favorable effects on MMSE score, hs-CRP, TAC, GSH, markers of
insulin metabolism, triglycerides, VLDL-, LDL-, total-/HDL-choles-
terol, but it did not affect other biomarkers of inﬂammation and
oxidative stress, FPG and other lipid proﬁles. In addition, co-
supplementation improved gene expression of TNF-a, PPAR-g and
LDLR, but did not affect gene expression of IL-8 and TGF-b.
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